Drugs in Clinical Pipeline: SC-006 | Treatment of Colorectal Cancer (CRC)

SC-006 is an experimental drug being developed by AbbVie in collaboration with Stemcentrx, for treating patients with advanced colorectal cancer (CRC).

New Drug for Treating Colorectal Cancer

AbbVie, a global biopharmaceutical company, announced in April 2016 that it will acquire Stemcentrx to further boost it’s oncology pipeline. SC-006 is a fruit of the merger. Though the mechanism of action is not revealed, it could be directed against DLL3 (delta-like protein 3) like SC-002.

Drugs in Clinical Pipeline: BMS 986166 | Treatment of Ulcerative Colitis

BMS 986166 is an experimental drug being developed by Bristol-Myers Squibb for treating Ulcerative Colitis (UC). Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptom of active disease is abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Dietary changes may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission. These include aminosalicylates such as sulfasalazine, steroids, immunosuppressants such as azathioprine, and biological therapy. Removal of the colon by surgery may be necessary if the disease is severe.

New Drug for Treating Ulcerative Colitis

Preclinical development is ongoing, and Phase I development of an oral solution of BMS 986166 is planned in the US [1].

Drugs in Clinical Pipeline: RO7062931 | Treatment of Chronic Hepatitis B Virus | Antivirals Agents

RO7062931 is a new experimental drug being developed by Roche pharma for treating patients with Chronic Hepatitis B. Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. The virus is transmitted through contact with the blood or other body fluids of an infected person. An estimated 240 million people are chronically infected with hepatitis B (defined as hepatitis B surface antigen positive for at least 6 months). However, it can be prevented by currently available safe and effective vaccine.

New Drug for Treatment of Chronic Hepatitis B Virus

Drugs in Clinical Pipeline: AZD5718 | 5-Lipoxygenase Activating Protein (FLAP) Inhibitor | Treatment of Cardiovascular Disorders

AZD5178 is an orally available small molecule inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. In a 2016 publication, researchers have disclosed novel pyrazoles that inhibit 5 -lipoxygenase activating protein (FLAP) and therefore leukotriene production. The publication further reports the utility of such pyrazoles in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), such as atherosclerosis, coronary artery disease (CAD), coronary heart disease (CHD), heart failure (HF), high risk coronary artery disease (HRCAD), and abdominal aortic aneurysms (AAA). Also, methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds are disclosed.

Drugs in Clinical Pipeline: LY3041658 | Treatment of Skin Diseases | Monoclonal Antibody | Chemokine (CXC) Antagonist

LY3041658 is (expected to be a) monoclonal antibody that targets and specifically bind seven human ELR+ CXC chemokines. Such antibodies are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.